Annual report pursuant to Section 13 and 15(d)

Debt and Interest- Additional Information (Detail)

v3.19.1
Debt and Interest- Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 14, 2016
Feb. 13, 2014
Jan. 31, 2019
Sep. 30, 2017
Aug. 31, 2017
Jul. 31, 2017
Jun. 30, 2017
May 31, 2017
May 02, 2017
Mar. 31, 2017
Jun. 30, 2016
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jun. 26, 2017
Dec. 31, 2015
Mar. 31, 2015
Debt [Line Items]                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                               125,000    
Warrant exercise price                           $ 8.50        
Debt Instrument, Interest Rate, Stated Percentage                         17.00%          
Debt Instrument, Face Amount                                 $ 900,000  
Notes Payable                         $ 79,503,000 $ 62,499,000       $ 10,000,000
Debt Instrument, Term                       36 months            
Fair Value Adjustment of Warrants                         682,000 $ 368,000        
Debt Instrument, Convertible, Terms of Conversion Feature                             (a) a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).      
Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights $ 1,500,000                                  
Legal Fees $ 25,000,000                                  
Class of Warrant or Right Exercise Price Description                           the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company .        
Proceeds from Convertible Debt                         0 $ 9,914,000        
Payments of Financing Costs                         0 81,000        
Debt Instrument Maturity Period Extention Description                       The Company may also use the proceeds to finance its subsidiaries. The notes mature 36 months from issuance, provided that during the first 24 months the Company may extend the maturity date by six months            
Debt Instrument Change in Periodic Interest Payment Description                       Interest on the note is 8% payable quarterly during the first 24 months (or the first 30 months if the note is extended) and monthly during the last 12 months            
Development Option and Stock Purchase Agreement [Member]                                    
Debt [Line Items]                                    
Fair Value Adjustment of Warrants                         $ 1,000,000          
Commercial Paper [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Face Amount                       $ 21,700,000            
Subsequent Event [Member] | Common Class B [Member]                                    
Debt [Line Items]                                    
Debt Conversion, Converted Instrument, Shares Issued     1,870,412                              
Letter of Credit [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Interest Rate, Stated Percentage                         2.00%          
Letters of Credit Outstanding, Amount                         $ 1,100,000          
Israel Discount Bank Of New York [Member]                                    
Debt [Line Items]                                    
Current portion of note payable                         $ 14,900,000 14,900,000        
Debt Instrument, Face Amount   $ 15,000,000                                
IDB Promissory Note Payable [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Interest Rate, Stated Percentage                         2.25%          
Debt Instrument, Face Amount   15,000,000                                
Debt Instrument, Unused Borrowing Capacity, Amount   100,000                                
Debt Instrument, Periodic Payment   $ 14,000,000                                
Opus Credit Facility [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Interest Rate, Stated Percentage                         12.00%          
Warrants and Rights Outstanding                         $ 9,500,000 $ 9,500,000        
Maturity Date                         Sep. 14, 2018          
NSC Notes Payable [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Interest Rate, Effective Percentage                           14.00%        
Helocyte Convertible Note One [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Interest Rate, Stated Percentage [1]                         8.00%          
Debt Instrument, Fee Amount                             $ 400,000      
Debt Instrument, Maturity Date, Description [1]                         December 2017          
Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights                             $ 400,000      
Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights                             110.00%      
Proceeds from Debt, Net of Issuance Costs                             $ 3,900,000      
Helocyte Convertible Note One [Member] | Conversion One [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Convertible, Terms of Conversion Feature                             (a) the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.      
Helocyte Convertible Note One [Member] | Maximum [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Face Amount                             $ 5,000,000      
Helocyte Convertible Note [Member]                                    
Debt [Line Items]                                    
Legal Fees                             $ 100,000      
Helocyte Convertible Note [Member] | Conversion One [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Convertible, Terms of Conversion Feature                     the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.              
Helocyte Convertible Note [Member] | Conversion Two [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Convertible, Terms of Conversion Feature                     a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).              
Caelum Convertible Note [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Face Amount           $ 10,000,000                        
Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights                           110.00%        
Class of Warrant or Right Exercise Price Description                           the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company.        
Debt Conversion, Description                           The notes convert upon a qualified financing in which Caelum raises gross proceeds of at least $10 million as follows: the lesser of (a) a discount to the price per common share being paid in the Sale of the Company equal to 20% or (b) a conversion price per share based on a pre-sale valuation of $75,000,000 divided by the number of common shares outstanding at that time assuming the hypothetical conversion or exercise of any convertible securities, options, warrants and other rights to acquire common shares of the Company.        
Percentage Of Placement Agent Fee                           10.00%        
Debt Instrument Issuance Percentage of Commission           10.00%               10.00%        
Proceeds from Convertible Debt                           $ 9,900,000        
Payments of Financing Costs                           $ 900,000        
NSC 2017 Note [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Interest Rate, Stated Percentage                   8.00%                
Debt Instrument, Face Amount                   $ 3,250,000                
Debt Instrument, Maturity Date, Description                   Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion.     Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion.          
Paid-in-kind Interest Percentage                   7.00%                
Line of Credit Facility, Current Borrowing Capacity                   $ 50,000,000                
Percentage Of Placement Agent Fee                   10.00%                
Warrant on Sale Price of Note Percentage                   10.00%                
NSC 2017 Note [Member] | First Closing [Member]                                    
Debt [Line Items]                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                   87,946                
Warrant exercise price                   $ 3.70                
Cash proceeds from 2008 Senior Convertible Notes                   $ 3,200,000                
Proceeds from Fees Received                   300,000                
NSC 2017 Note [Member] | Secoud Closing [Member]                                    
Debt [Line Items]                                    
Warrant exercise price                 $ 3.65                  
Cash proceeds from 2008 Senior Convertible Notes                 $ 8,600,000                  
Proceeds from Fees Received                 $ 900,000                  
NSC 2017 Note [Member] | Third Closing [Member]                                    
Debt [Line Items]                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights               147,806 234,438                  
Warrant exercise price               $ 3.61                    
Cash proceeds from 2008 Senior Convertible Notes               $ 5,300,000                    
Proceeds from Fees Received               $ 500,000                    
NSC 2017 Note [Member] | Fourth Closing [Member]                                    
Debt [Line Items]                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights             38,315                      
Warrant exercise price             $ 4.75                      
Cash proceeds from 2008 Senior Convertible Notes             $ 1,800,000                      
Proceeds from Fees Received             $ 200,000                      
NSC 2017 Note [Member] | Fifth Closing [Member]                                    
Debt [Line Items]                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights         63,526                          
Warrant exercise price         $ 4.75                          
Cash proceeds from 2008 Senior Convertible Notes         $ 3,000,000                          
Proceeds from Fees Received         $ 300,000                          
NSC 2017 Note [Member] | Sixth Closing [Member]                                    
Debt [Line Items]                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       144,149                            
Warrant exercise price       $ 4.42                            
Cash proceeds from 2008 Senior Convertible Notes       $ 6,400,000                            
Proceeds from Fees Received       $ 600,000                            
NSC 2017 Note [Member] | Maximum [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Face Amount                   $ 40,000,000                
Venture Note [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Interest Rate, Stated Percentage                       8.00% 8.00%          
Debt Instrument, Maturity Date, Description                         February - 2021          
DOSPA [Member]                                    
Debt [Line Items]                                    
Debt Instrument, Face Amount                         $ 9,900,000          
DOSPA [Member] | Subsequent Event [Member]                                    
Debt [Line Items]                                    
Sale of Stock, Consideration Received on Transaction     $ 30,000,000                              
Sale of Stock Percentage of Shares Transferred on Transaction     19.90%                              
NSC [Member] | Venture Note [Member]                                    
Debt [Line Items]                                    
Warrant on Sale Price of Note Percentage                         25.00%          
Payments of Financing Costs                       $ 1,700,000            
Class Of Warrant Or Right Expiration Period                         10 years          
Aevitas Therapeutics Inc [Member] | Venture Note [Member]                                    
Debt [Line Items]                                    
Cash proceeds from 2008 Senior Convertible Notes                         $ 2,200,000          
Tamid Bio Inc [Member] | Venture Note [Member]                                    
Debt [Line Items]                                    
Cash proceeds from 2008 Senior Convertible Notes                         1,400,000          
Cellvation [Member] | Venture Note [Member]                                    
Debt [Line Items]                                    
Cash proceeds from 2008 Senior Convertible Notes                         1,100,000          
Cyprium [Member] | Venture Note [Member]                                    
Debt [Line Items]                                    
Cash proceeds from 2008 Senior Convertible Notes                         $ 1,700,000          
[1] Classified as short-term on the Company’s Consolidated Balance Sheet as of December 31, 2017.